New molecular blocker halts breastcancer metastasis, says study
Dissemination of cancer cells from the primary tumor into distant body tissues and organs is the leading cause of death in cancer patients. While most clinical strategies aim to reduce or impede the growth of the primary tumor, no treatment to eradicate metastatic cancer exists at present.
The Pyk2-PRR2 peptide blocks spontaneous lung metastasis in immune-competent mice by inhibiting cortactin tyrosine phosphorylation and actin polymerization-mediated maturation and activation of invadopodia, leading to reduced MMP-dependent tumor cell invasiveness.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Millie Mackintosh gets ‘new year new hair’ makeover and feels ‘like a new woman’Mum-of-two Millie Mackintosh is kicking off 2023 with a brand new hair colour and cut to feel ‘ready to embrace the year ahead’ – and even her brows got some TLC too
続きを読む »
M&S announce 20 new store openings, 12 food halls and the creation of 3400 new jobsMarks & Spencer has announced it's set to open 20 new stores across the country - including 12 food halls, creating 3,400 new jobs over the next two years.
続きを読む »
Plans approved for new Derry Girls exhibit and new trailDerry City and Strabane District Council has approved funding for a new Derry Girls exhibition in the city
続きを読む »
Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness - Cancer Cell InternationalThe tumor suppressor p53 when undergoes amyloid formation confers several gain-of-function (GOF) activities that affect molecular pathways crucial for tumorigenesis and progression like some of the p53 mutants. Even after successful cancer treatment, metastasis and recurrence can result in poor survival rates. The major cause of recurrence is mainly the remnant cancer cells with stem cell-like properties, which are resistant to any chemotherapy treatment. Several studies have demonstrated the role of p53 mutants in exacerbating cancer stemness properties and epithelial-mesenchymal transition in these remnant cancer cells. Analyzing the amyloid/mutant p53-mediated signaling pathways that trigger metastasis, relapse or chemoresistance may be helpful for the development of novel or improved individualized treatment plans. In this review, we discuss the changes in the metabolic pathways such as mevalonate pathway and different signaling pathways such as TGF-β, PI3K/AKT/mTOR, NF-κB and Wnt due to p53 amyloid formation, or mutation. In addition to this, we have discussed the role of the regulatory microRNAs and lncRNAs linked with the mutant or amyloid p53 in human malignancies. Such changes promote tumor spread, potential recurrence, and stemness. Importantly, this review discusses the cancer therapies that target either mutant or amyloid p53, restore wild-type functions, and exploit the synthetic lethal interactions with mutant p53.
続きを読む »
Exclusive: New Girl's Hannah Simone on why new series Not Dead Yet is breaking more boundariesNew Girl cast member Hannah Simone details new ABC series Not Dead Yet and shares New Girl reunion news
続きを読む »
Love Island first look sees Maya Jama arrive by helicopter as the Islanders meetThe first look of the new Love Island series sees new host Maya Jama arrive in epic style, landing in a helicopter as the 2023 Islanders meet for the first time
続きを読む »